U.S. markets close in 8 minutes
  • S&P 500

    4,064.16
    -12.41 (-0.30%)
     
  • Dow 30

    34,371.25
    -23.76 (-0.07%)
     
  • Nasdaq

    11,463.78
    -18.67 (-0.16%)
     
  • Russell 2000

    1,893.82
    +12.14 (+0.65%)
     
  • Crude Oil

    80.28
    -0.94 (-1.16%)
     
  • Gold

    1,812.40
    -2.80 (-0.15%)
     
  • Silver

    23.42
    +0.57 (+2.51%)
     
  • EUR/USD

    1.0539
    +0.0010 (+0.09%)
     
  • 10-Yr Bond

    3.5060
    -0.0230 (-0.65%)
     
  • GBP/USD

    1.2283
    +0.0027 (+0.22%)
     
  • USD/JPY

    134.2830
    -1.0230 (-0.76%)
     
  • BTC-USD

    17,002.69
    +66.13 (+0.39%)
     
  • CMC Crypto 200

    404.05
    +2.63 (+0.66%)
     
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • Nikkei 225

    27,777.90
    -448.18 (-1.59%)
     

Axsome Therapeutics (AXSM) Gains But Lags Market: What You Should Know

Axsome Therapeutics (AXSM) closed at $45.33 in the latest trading session, marking a +1.59% move from the prior day. This move lagged the S&P 500's daily gain of 2.59%. Elsewhere, the Dow gained 2.66%, while the tech-heavy Nasdaq added 0.11%.

Heading into today, shares of the biopharmaceutical company had lost 29.16% over the past month, lagging the Medical sector's loss of 3.87% and the S&P 500's loss of 9.22% in that time.

Investors will be hoping for strength from Axsome Therapeutics as it approaches its next earnings release. In that report, analysts expect Axsome Therapeutics to post earnings of -$1.23 per share. This would mark a year-over-year decline of 32.26%.

Investors should also note any recent changes to analyst estimates for Axsome Therapeutics. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 1.42% lower. Axsome Therapeutics is currently a Zacks Rank #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 85, which puts it in the top 34% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research